Skip to main content

Table 3 Disease progression incidence rate, PFS time and OS time

From: Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study

  Disease progression incidence rate Kaplan-Meir estimated progression-free survival Kaplan-Meier-estimated overall survival
N Patients with disease progression assessment Total follow up time in first line treatment (years) Incidence Rate (95% CI)
(person-years)
N 12-month PFS Median PFS (95% CI) (months) Hazard Ratio
(95% CI); p-value, univariate analysis
N 12-month survival rate Median OS(95% CI) (months) Hazard Ratio (95% CI); p-value; univariate analysis
Overall patient population
  357 147 256.7 0.57
(0.48–0.67)
373 76.0
(71.2–80.1)
22.4
(20.4–24.7)
n/a 379 88.8
(85.1–91.6)
45.0
(40.9–55.0)
n/a
Patient subpopulations per MBC diagnosis state  
First diagnosed at an earlier stage 208 110 129.1 0.85
(0.69–1.01)
221 68.1
(59.7–75.1)
20.4
(17.8–22.8)
1.42
(1.12–1.81);
p = 0.004
227 87.9
(82.9–91.6)
41.0
(36.9–48.4)
1.37
(0.97–1.93); p = 0.073
de novo Diagnosis 149 37 127.6 0.29
(0.20–0.38)
152 82.7
(75.5–88.0)
26.8
(21.8–30.3)
152 90.1
(84.1–93.9)
not reached
Patient subpopulations per HR/HER2 status  
HR+/HER2 182 76 161.0 0.47
(0.37–0.58)
187 79.2
(72.5–84.5)
24.6
(21.3–27.9)
HR+/HER2+ vs. HR+/HER2
1.48 (1.05–2.09); p = 0.027
HR/HER2+ vs. HR+/HER2
1.21 (0.82–1.77); p = 0.337
HR/HER vs. HR+/HER2
1.52 (1.06–2.16); p = 0.023
189 94.1
(89.6–96.7)
48.4
(36.3–61.0)
HR+/HER2+ vs. HR+/HER21.00 (0.60–1.68); p = 0.992
HR/HER2+ vs. HR+/HER21.71 (1.05–2.78); p = 0.032
HR/HER vs. HR+/HER21.79 (1.12–2.87); p = 0.015
HR+/HER2+ 51 21 29.7 0.71
(0.40–1.01)
55 67.5
(53.0–78.4)
19.7
(12.9–25.9)
56 89.3
(77.7–95.0)
45.6
(21.5–65.3)
HR/HER2+ 43 22 25.5 0.86
(0.50–1.22)
42 85.6
(70.8–93.3)
23.0
(16.6–29.7)
43 92.9
(79.5–97.6)
34.0
(25.5–45.6)
HR/HER2 45 16 19.9 0.80
(0.41–1.20)
47 62.2
(46.3–74.6)
18.3
(10.0–24.7)
49 72.9
(58.1–83.3)
40.4
(18.4–55.0)
  1. Disease progression incidence rate, and the Kaplan-Meier estimated PFS time and OS time along with the 95% confidence intervals and hazard ratios of univariate analyses (p-values in bold indicated statistical significance) are displayed in the overall population and subpopulations per state of MBC diagnosis and HR/HER2 status. CI, confidence interval; N, number of patients analyzed for each outcome; n/a, not applicable
\